About
About Dr. Damon Tojjar
Physician-scientist (M.D., Ph.D. candidate) and digital health entrepreneur whose work spans global drug development, clinical AI and decision support, medical-device regulation, and the critical appraisal of clinical evidence across medicine, from the research bench to validated clinical implementation.
Dr. Damon Tojjar is a physician-scientist and digital health entrepreneur whose work spans global drug development, clinical AI, and medical-device regulation, with research roots in diabetes genetics and metabolic disease. Trained in medicine at Lund University and in systems medicine at Stanford, his diabetes-genetics research includes a shared (co-second) author contribution to a paper in Science, recognized with the Magnus Blix Award, and a Diabetes Care meta-analysis cited more than 800 times. He co-developed EASY Diabetes, an AI decision-support system that won Sweden's Medtech4Health Innovation Award, and co-founded Vi-Health, which was selected as one of 20 finalists (Top 20 Deep Tech) in the EIT Digital Challenge and later acquired by Numan. In academic citations his work appears under the name Tojjar, D.
Training and credentials
- M.D., Lund University (conferred)
- Ph.D. candidate, medical science, Lund University Diabetes Centre (in progress)
- Research Fellow in Systems Medicine, Stanford University School of Medicine; Anna Lindh Fellow
- Medical Device Regulations training, KTH Royal Institute of Technology (EU MDR, IVDR, FDA, Software as a Medical Device); FDA Clinical Investigator training
What he writes about
Dr. Tojjar publishes rigorously cited, non-promotional evidence-appraisal explainers across clinical medicine: how to read a study and judge medical evidence; validating and governing healthcare AI; medical-device and drug regulation and Good Clinical Practice; preventive care and screening; cardiovascular, imaging, oncology, neurology, infectious-disease and internal-medicine literacy; metabolic health; therapeutic peptides; and non-partisan health policy. He writes as an explainer and evaluator of the research, grounded in his own diabetes-genetics work and his applied work building and validating clinical AI.
Awards
Magnus Blix Award; Medtech4Health Innovation Award; EIT Top 20 Deep Tech; Anna Lindh Fellowship.
Selected publications
- Science: Overexpression of alpha2A-adrenergic receptors contributes to type 2 diabetes
- Diabetes Care: Ethnic differences in the relationship between insulin sensitivity and insulin response
- Diabetologia: Polymorphisms in the Ca2+ channel CaV2.3 (CACNA1E) and type 2 diabetes
- Diabetes, Obesity and Metabolism: Comparison of insulin degludec with insulin detemir in type 1 diabetes
How to read this site
This site explains and evaluates published medical evidence. Dr. Tojjar writes as a physician-scientist and reference voice; he does not provide medical care, treat patients, or offer individual medical advice here. For guidance about your own health, talk with a qualified clinician. His fully sourced verified record is at damontojjar.com/record.